Generic makers fall short when providing access to low- and middle-income countries, analysis finds
The article looks at the potential for generic and biosimilar companies to do so much more to expand access, and how the report identifies where they're falling short.
The Foundation's CEO, Jayasree Iyer, is quoted: “Today, the generics industry focuses mainly still on their domestic market and the U.S. and Europe, while there are many opportunities worldwide. So they are feeling the pressures, too, like the big research-based companies. (These) companies need to go from the transactional tender-based mechanisms and complement that with much more effort to reach underserved populations, and be more transparent about their actions.”
Read the Foundation's report on generic and biosimilar medicine manufacturers.